Craft

Evotec

Stock Price

€7.2

2024-10-29

Market Capitalization

€1.3 B

2024-10-29

Revenue

€781.4 M

FY, 2023

Evotec Summary

Company Summary

Overview
Evotec is a biotechnology company that provides drug discovery and development services. It operates through two operating segments: EVT Execute and EVT Innovate. The company mainly focuses on oncology, CNS disorders, auto-immune and infectious diseases, cardiometabolic disorders, and fibrotic and respiratory diseases. Evotec caters to pharmaceutical companies, biotechs, foundations, and government agencies.
Type
Public
Status
Active
Founded
1993
HQ
Hamburg, DE | view all locations
Website
https://www.evotec.com/en/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Craig Johnstone

    Craig Johnstone, Chief Operating Officer

  • Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer

  • Volker Braun

    Volker Braun, Head of Global Investor Relations & ESG

  • Laetitia Rouxel

    Laetitia Rouxel, Chief Financial Officer

Operating MetricsView all

Scientists and Researchers

4.2K
4.3%

FY, 2023

Projects

110

FY, 2023

New Customers

298
8.3%

FY, 2023

LocationsView all

16 locations detected

  • Hamburg, HH HQ

    Germany

    Essener Bogen 7

  • Branford, CT

    United States

    33 Business Park Drive #6

  • Princeton, NJ

    United States

    303B College Road East

  • Redmond, WA

    United States

    22857 NE Marketplace Drive

  • Seattle, WA

    United States

    401 Terry Ave N

  • Orth an der Donau, Niederösterreich

    Austria

    Uferstraße 15

and 10 others

Evotec Financials

Summary Financials

Revenue (Q3, 2024)
€184.9M
Gross profit (Q3, 2024)
(€19.8M)
Net income (Q3, 2024)
(€39.6M)
Cash (Q3, 2024)
€231.3M
EBIT (Q3, 2024)
(€31.7M)
Enterprise value
$1.5B

Footer menu